---
title: "Hepion Pharmaceuticals, Inc. (HEPA.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/HEPA.US.md"
symbol: "HEPA.US"
name: "Hepion Pharmaceuticals, Inc."
industry: "制药"
---

# Hepion Pharmaceuticals, Inc. (HEPA.US)

| Item | Detail |
|------|--------|
| Industry | 制药 |
| Location | 美股市场 |
| Website | [epionpharma.com](https://epionpharma.com) |

## Company Profile

Hepion Pharmaceuticals, Inc.是一家生物制药公司，专注于在美国开发肝细胞癌（HCC）和其他慢性肝病的治疗。该公司开发了 Rencofilstat，这是一种治疗药物候选者，能够结合并抑制一种特定类别的异构酶——环孢素酶的功能，这种酶调节蛋白质折叠。此外，Rencofilstat 的临床前实验显示出肝纤维化、肝炎、肝肿瘤负担以及 HBV、HCV、HDV 和 HIV-1 的滴度均有所降低。该公司之前被称为 ContraVir Pharmaceuticals, Inc.，后来更名为 Hepion Pharmaceuticals, Inc

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.05 | 63/257 | - | - | - |
| PB | 0.29 | 12/257 | 0.44 | 0.37 | 0.30 |
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview](https://longbridge.com/en/quote/HEPA.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/HEPA.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/HEPA.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
